top of page
The Professional Network for Healthcare Experts
argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery
argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics.
nuaxia
23 hours ago2 min read
Zealand Pharma licenses GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes
Zealand Pharma has licensed its GLP-1/gastrin dual-agonist peptide platform to Elvinix for development as a potentially regenerative treatment for type 1 diabetes.
nuaxia
Sep 172 min read
Aizen Therapeutics signs AI peptide collaboration worth up to $100 million per target
The multi-program deal pairs Aizen’s DaX AI platform with an undisclosed San Diego biotechnology company to design oral peptide therapeutics against nominated immunology and neurology targets.
nuaxia
Aug 173 min read
bottom of page